Perspective Therapeutics terminates Chief R&D Officer Cavanagh; separation payment of $341,000

Perspective Therapeutics, Inc.

William Cavanagh III departed as Chief R&D Officer effective Feb 7, 2023; Separation Agreement effective Mar 10, 2023.
Cavanagh receives $341,000 (12 months base salary) paid biweekly, plus health premium equivalent for one year.
Separation includes full release of claims against the company and confidentiality/non-disparagement obligations.
Stock options: unvested options terminate; vested options expire 90 days from Feb 7, 2023.
Agreement includes 45-day consideration period and 7-day revocation period under ADEA.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William Cavanagh III

Chief Research and Development Officer

CATX · Perspective Therapeutics, Inc.

Filed: March 13, 2023, 7:59 PM ET

In connection with the termination of William Cavanagh III from his position of Chief Research and Development Officer of Perspective Therapeutics, Inc. (the “ Company ”), as previously disclosed on the Form 8-K filed by the Company on February 10, 2023, the Company, Isoray Medical, Inc. (a wholly-owned subsidiary of the Company), and Mr. Cavanagh entered into a Separation Agreement effective March 10, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William Cavanagh III was terminated as Chief Research and Development Officer at Perspective Therapeutics, Inc..

Action: terminated
Role: Chief Research and Development Officer

Exact text from the filing

In connection with the termination of William Cavanagh III from his position of Chief Research and Development Officer of Perspective Therapeutics, Inc. (the “ Company ”), as previously disclosed on the Form 8-K filed by the Company on February 10, 2023, the Company, Isoray Medical, Inc. (a wholly-owned subsidiary of the Company), and Mr. Cavanagh entered into a Separation Agreement effective March 10, 2023.

View on SEC.gov

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-006382

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.